Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
PF-5006739
Cat. No.:
OB0425LY-087
Appearance:
Solid
Purity:
99.56%
Identity:
Confirmed by NMR, HPLC, and MS.
Size:
Add to basket
Product Overview
Description:
PF-5006739 is a potent and selective CK1δ/ε inhibitor.
Synonyms:
1293395-67-1; PF 5006739; 2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-[1-(3-isoxazolylmethyl)-4-piperidinyl]-1H-imidazol-5-yl]-; 4-[4-(4-Fluorophenyl)-1-[1-(3-isoxazolylmethyl)-4-piperidinyl]-1H-imidazol-5-yl]-2-pyrimidinamine
CAS No.:
1293395-67-1
Compound CID:
51353555
Formula:
C22H22FN7O
Formula Weight:
419.45
Specification
Target:
Casein kinase
Pathway:
Cell cycle/DNA damage; Stem cell/Wnt
Solubility:
DMSO
Storage:
Storage at 4°C.
Applications:
PF-5006739 can be used to improve glucose tolerance in diet-induced obesity (DIO) and genetic obesity (ob/ob) mouse models.
